Published by Josh White on 22nd December 2022
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to finalise a partnering agreement for 'NTCD-M3', which it described as its "most advanced" clinical programme, targeted at infection prevention.
URL: http://www.digitallook.com/dl/news/story/33197073/...